Updated guidelines for anaphylaxis management - simplified structures for enhanced patient safety

The updated Swedish guidelines for anaphylaxis, published by the Swedish Association for Allergology (SFFA) in the autumn of 2024, provide evidence-based recommendations for acute care. The guidelines highlight the importance of rapid intervention and clear diagnostic standards to ensure patient safety. Immediate intramuscular administration of adrenaline is the only evidence-based intervention in the acute phase and should occur without delay or consideration of severity grading. Routine use of corticosteroids is no longer recommended, and severity grading is replaced by NIAID/FAAN criteria. Antihistamines are reserved for post-stabilization. Documentation, observation, and control of serum tryptase levels are essential for continued care, diagnostic accuracy, and long-term management.

Published by Lakartidningen, 2025. The guideline itself is at the source linked here.

pubmed.ncbi.nlm.nih.gov/41408837/